CRSP:NSD-CRISPR Therapeutics AG (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 97.00

Change

0.00 (0.00)%

Market Cap

USD 7.39B

Volume

1.85M

Avg Analyst Target

USD 149.33 (+53.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Address: Baarerstrasse 14, Zug, Switzerland, 6300

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD133.96B 39.21 29.43
BNTX BioNTech SE

N/A

USD60.07B 13.83 10.18
REGN Regeneron Pharmaceuticals Inc

N/A

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD33.45B N/A N/A
SGEN Seagen Inc

N/A

USD31.43B 53.89 40.74
GMAB Genmab A/S

N/A

USD29.05B 74.91 8.12
ALNY Alnylam Pharmaceuticals Inc

N/A

USD24.79B N/A N/A
RPRX Royalty Pharma plc

N/A

USD23.31B 31.09 11.82

ETFs Containing CRSP

Symbol Name Weight Mer Price(Change) Market Cap
AIIQ AI Powered International .. 0.00 % 0.79 %

N/A

USD0.01B
ERSX Entrepreneurshares Series.. 0.00 % 0.75 %

N/A

USD0.04B
LS:CA Middlefield Healthcare & .. 0.00 % 1.31 %

N/A

USD0.08B
2B78:XETRA iShares IV Public Limited.. 0.00 % 0.40 %

N/A

USD2.37B
BBIG:CA Horizons Global BBIG Tech.. 0.00 % 0.00 %

N/A

N/A
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -36.65% 29% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.65% 29% F 13% F
Trailing 12 Months  
Capital Gain -11.68% 48% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.68% 48% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 82.19% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.19% 85% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 86.20% 35% F 20% F
Risk Adjusted Return 95.35% 98% A+ 92% A-
Market Capitalization 7.39B 96% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.43 36% F 52% F
Price/Book Ratio 2.95 57% F 45% F
Price / Cash Flow Ratio -31.01 83% B 83% B
EV/EBITDA 11.48 30% F 59% F
Management Effectiveness  
Return on Equity 25.41% 97% A+ 90% A-
Return on Invested Capital -27.29% 73% C 25% F
Return on Assets 14.19% 98% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.86 63% D 52% F
Short Percent 4.02% 60% D- 40% F
Beta 2.25 11% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector